Biomarker Partnering Terms & Agreements Disclosed in In-Demand Report by CurrentPartnering26 Apr 2013 • by Natalie Aster
A detailed understanding and analysis of how and why companies enter biomarker partnering deals are provided in the report “Biomarker Partnering Terms and Agreements” by CurrentPartnering. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details on the latest biomarker deals announced in the healthcare sectors. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all biomarker partnering deals announced since 2007 including financial terms where available including over 750 links to online deal records. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Biomarker Partnering Terms and Agreements
Published: March, 2013
Price: US$ 2,795.00
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.
More information can be found in the report “Biomarker Partnering Terms and Agreements” by CurrentPartnering.
To order the report or ask for sample pages contact firstname.lastname@example.org